What's Happening?
Accellix, Inc., a leader in automated flow cytometry, has partnered with Streck, a company known for quality control materials in diagnostics, to integrate the Accellix Automated Cell Phenotyping Platform with Streck's CD-Chex Plus (RUO) control. This collaboration aims to streamline the quality control process in cell therapy by automating cell phenotyping, which traditionally requires complex instrumentation and specialized operators. The Accellix platform uses microfluidic cartridges to automate processes from antibody staining to data analysis, ensuring rapid and reproducible results. The integration with CD-Chex Plus (RUO) allows users to monitor the platform's performance, maintaining trust in their data without needing centralized lab infrastructure.
Why It's Important?
This collaboration is significant for the cell therapy industry, as it addresses the need for reliable and efficient quality control processes. By simplifying flow cytometry quality control, Accellix and Streck are helping laboratories and cell therapy developers achieve faster and more reliable results. This can lead to improved outcomes in healthcare, as accurate and efficient quality control is crucial for the development and implementation of life-changing therapies. The partnership also highlights the importance of innovation in biotechnology, as companies seek to enhance the reliability and efficiency of their processes.
What's Next?
The Accellix Automated Cell Phenotyping Platform will be integrated with the CD-Chex Plus (RUO) control starting with lot 5265, which is set to ship on September 22, 2025. This rollout will allow users to begin utilizing the enhanced quality control capabilities immediately. As the collaboration progresses, it is expected that more laboratories and cell therapy developers will adopt this integrated solution, potentially leading to broader improvements in cell therapy quality control across the industry.
